Clinical Trial Update: Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Tecemotide (L-BLP25) in slowly progressive, asymptomatic multiple myeloma patients who had no prior chemotherapy; the trial completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Tecemotide (L-BLP25)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2016-02-22